Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • PharmAkea

    - PMLiVE

    Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

    Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

    Uniphar

    Dave Miller on Biotechs image

    Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

    HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

    Genesis Research Group

    - PMLiVE

    Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

    The candidate is currently under review for both interstitial lung diseases in the EU and US

    - PMLiVE

    Medscape Education Global to Join Biotechs at Swiss Biotech Day

    The Medscape Education Global team is excited to announce its participation in Swiss Biotech Day, taking place in Basel from May 5-6. This marks our inaugural attendance at this event,...

    Medscape Education

    - PMLiVE

    Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

    About 100,000 people are living with the progressive condition in the US alone

    - PMLiVE

    Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

    Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

    Avalere Health

    - PMLiVE

    Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

    Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

    Mike Bushell presenting PMEA award to two Bedrock employees

    Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence

    Recognition for a bold and imaginative approach to an actionable clinical consensus for MS patients.

    Bedrock Healthcare Communications

    - PMLiVE

    Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial

    BI 1015550 reduced the rate of lung function decline in patients with IPF in a phase 2 trial

    - PMLiVE

    AbbVie to acquire DJS Antibodies in $255m cash deal

    The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

    - PMLiVE

    The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

    With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

    Avalere Health

    Biotech Innovation in the Time of COVID-19

    Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

    Impetus Digital

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links